StockNews.com initiated coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report report published on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on NKTR. TD Cowen upgraded shares of Nektar Therapeutics from a market perform rating to an outperform rating in a research note on Thursday, November 9th. Mizuho reiterated a neutral rating and set a $6.00 target price on shares of Nektar Therapeutics in a research report on Monday, August 7th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Hold and an average target price of $3.00.
Nektar Therapeutics Trading Up 8.0 %
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of NKTR. Monaco Asset Management SAM purchased a new position in Nektar Therapeutics during the 2nd quarter valued at about $5,327,000. Marquette Asset Management LLC purchased a new stake in Nektar Therapeutics during the 2nd quarter worth about $85,000. CM Management LLC lifted its position in Nektar Therapeutics by 220.0% during the 1st quarter. CM Management LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 275,000 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Nektar Therapeutics by 597.5% in the 2nd quarter. Acadian Asset Management LLC now owns 4,396,020 shares of the biopharmaceutical company’s stock valued at $2,528,000 after acquiring an additional 3,765,771 shares during the last quarter. Finally, Deep Track Capital LP grew its stake in Nektar Therapeutics by 931.0% during the 2nd quarter. Deep Track Capital LP now owns 17,973,464 shares of the biopharmaceutical company’s stock worth $10,338,000 after buying an additional 16,230,216 shares during the last quarter. 82.20% of the stock is owned by hedge funds and other institutional investors.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer.
- Five stocks we like better than Nektar Therapeutics
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- The most upgraded stocks in November have two things in common
- What is a Secondary Public Offering? What Investors Need to Know
- Monday.com rocked earnings like it’s the weekend
- Conference Calls and Individual Investors
- Plan to own one retailer? Make it this one
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.